Clients

Selection of current and past services delivered to clients

Strategic consultancy

  • Multiple sclerosis, major pharma company, US, 2019
  • Multiple sclerosis, major pharma company, EU, 2016 – 2019
  • Epilepsy, mid-sized pharma company, EU, 2018
  • Paediatric epilepsy, mid-sized pharma company, EU, 2015 - 2016
  • In-licencing, neuroendocrine tumour, mid-sized pharma company, EU, 2014 - 2015
  • Biosimilar in multiple sclerosis, mid-sized pharma company, EU, 2010 – 2017
  • Cognitive disorder, CRO and start-up company, EU, 2014
  • Neurodegeneration in multiple sclerosis, major pharma company, MENA region, 2014
  • Liposomal drug delivery to the brain, start-up company, EU, 2014
  • Follow-on compound in multiple sclerosis, mid-sized pharma company, EU, 2012 – 2013
  • In-licencing, biosimilar in multiple sclerosis, mid-sized pharma company, EU, 2012 – 2013
  • Translational project in spinal-cord injury, bank, EU, 2011

Interim management at global level

  • Multiple sclerosis Phase IIIb and managed access, major pharma company, EFTA region, 2017 - 2018
  • Multiple sclerosis Phase III, major pharma company, EFTA region, 2015 - 2016
  • Multiple sclerosis Phase II, major pharma company, EFTA region, 2015
  • Fragile X syndrome Phase III, major pharma company, EFTA region, 2014 - 2015
  • Multiple sclerosis Phase II, major pharma company, EFTA region, 2009 – 2010

Member of scientific Advisory Boards

  • Multiple sclerosis, major pharma company, EU, 2016 - 2019
  • Acute neurological condition, start-up company, EU, 2014
  • Neuro-ophthalmology, major pharma company, EFTA region, 2012
  • Multiple sclerosis, mid-sized pharma company, EU, 2010 – 2012
  • Multiple sclerosis, major pharma company, EFTA region, 2010

Member of Study Steering Committees

  • Long-term follow-up study, major pharma company, EFTA region, 2014 – 2017
  • Global biosimilar study, mid-sized pharma company, EU, 2011 – 2015

Speaker at scientific satellite events

  • Multiple sclerosis, major pharma company, EU, 2016 - 2019

Medical expertise in neurology, neuro-ophthalmology, immunology, and stroke

  • Major pharma company, EFTA region, 2015 - 2018
  • Mid-sized pharma company, EU, 2014 – 2015
  • Major pharma company, EFTA region, 2009 – 2014

Scientific intelligence in neurological indications

  • Mid-sized pharma company, EU, 2012 – 2014
  • Mid-sized pharma company, EU, 2012 – 2013

Coaching and training of employees in drug development and multiple sclerosis

  • Major pharma company, EFTA region, 2018
  • Major pharma company, EFTA region, 2015 – 2016
  • Major pharma company, EFTA region, 2012 – 2014
  • Mid-sized pharma company, EU, 2013